Phase 3 Trial of Carboplatin in Triple Negative Breast Cancer (TNBC
Phase 3 Trial of Carboplatin in Triple Negative Breast Cancer (TNBC) Patients with Residual Invasive Carcinoma After Neoadjuvant Chemotherapy (JONIE4:J-CAT Trial) Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N. Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan. Background: Trial design: Eligibility criteria: This is an open label, randomized phase III study that will enroll TNBC with residual invasive 1) ER and PgR<1%, HER2 0, 1+ or 2+ with FISH negative on core needle biopsy before the It is well known that the prognosis of non pCR TNBC patients was poor after anthracycline chemotherapy and surgical specimens. and taxan treatment. For such patients, capecitabine seems to be effective to reduce cancer after surgery with preoperative chemotherapy including both anthracycrine and taxan.
[Show full text]